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Abstract
FOXP transcription factors play important roles in neurodevelopment, but little is known about how their transcriptional
activity is regulated. FOXP proteins cooperatively regulate gene expression by forming homo- and hetero-dimers with each
other. Physical associations with other transcription factors might also modulate the functions of FOXP proteins. However,
few FOXP-interacting transcription factors have been identified so far. Therefore, we sought to discover additional transcrip-
tion factors that interact with the brain-expressed FOXP proteins, FOXP1, FOXP2 and FOXP4, through affinity-purifications of
protein complexes followed by mass spectrometry. We identified seven novel FOXP-interacting transcription factors (NR2F1,
NR2F2, SATB1, SATB2, SOX5, YY1 and ZMYM2), five of which have well-estabslished roles in cortical development.
Accordingly, we found that these transcription factors are co-expressed with FoxP2 in the deep layers of the cerebral cortex
and also in the Purkinje cells of the cerebellum, suggesting that they may cooperate with the FoxPs to regulate neural gene
expression in vivo. Moreover, we demonstrated that etiological mutations of FOXP1 and FOXP2, known to cause neurodeve-
lopmental disorders, severely disrupted the interactions with FOXP-interacting transcription factors. Additionally, we pin-
pointed specific regions within FOXP2 sequence involved in mediating these interactions. Thus, by expanding the FOXP inter-
actome we have uncovered part of a broader neural transcription factor network involved in cortical development, providing
novel molecular insights into the transcriptional architecture underlying brain development and neurodevelopmental
disorders.
Introduction
Transcription factors have emerged as a key class of genes dis-
rupted in monogenic forms of neurodevelopmental disorders
such as intellectual disability (ID) and autism spectrum disorder
(ASD), consistent with the precise temporal and spatial control
of gene expression that underpins neurodevelopmental proc-
esses (1). Large-scale next-generation DNA sequencing studies
have been particularly successful in identifying monogenic ID/
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ASD-related disorders caused by high-penetrance de novo muta-
tions in transcription factor genes (2–4).
Among the many families of human transcription factors,
the FOXP subfamily of forkhead box proteins is notable for the
neurodevelopmental phenotypes which have been associated
with their disruption (5,6). The FOXP family includes four pro-
teins: FOXP1, FOXP2, FOXP3 and FOXP4 (7). FOXP1, FOXP2 and
FOXP4 exhibit 55–65% sequence identity and show overlapping
expression in the developing brain, as well as in other organs
(7,8). FOXP3 is structurally divergent and its expression is
limited to T lymphocytes (9). FOXP3 disruption causes an
immunological disorder, IPEX (immunodysregulation polyen-
docrinopathy enteropathy X-linked, OMIM #304790) syndrome,
while mutations of FOXP1, FOXP2 and FOXP4 have each been
linked to distinct neurodevelopmental disorders. Heterozygous
disruptions of FOXP1 cause a broad neurodevelopmental syn-
drome, which includes global developmental delay and ID, fre-
quently accompanied by features of autism and impaired
speech and language abilities (OMIM #613670) (10–14). All patho-
genic variants observed to date have occurred de novo, consis-
tent with the severe phenotype of the disorder (14).
Heterozygous disruptions of FOXP2 cause a rare monogenic
form of speech and language impairment including childhood
apraxia of speech as a core feature (OMIM #602081) (15–21).
Unlike FOXP1-associated disorder, general cognitive functions
may be within the normal range, and both inherited and de novo
cases have been reported (22). Although the FOXP2-related dis-
order is less severe than that resulting from FOXP1 disruption,
individuals with FOXP2 and FOXP1 mutations display overlap-
ping features such as language impairment, suggesting that the
syndromes may involve disruption of similar molecular and cel-
lular networks (23).
Disorders relating to FOXP4 disruption had not been
reported until recently, when Charng et al. described a homozy-
gous frameshift variant in a child from a consanguineous family
affected by developmental delay and malformations in the lar-
ynx and the heart (6). It is interesting that this, the only cur-
rently suspected case of FOXP4-related disorder, involves a
recessive mutation, in contrast to the dominant disorders
described for FOXP1 and FOXP2 disruptions. The potential com-
plete absence of FOXP4 protein in this child may also explain
why the disorder appears to have broader effects in organs
other than the brain. Indeed, all three neurally-expressed FOXP
proteins also have roles in the development of other organs, but
their neurodevelopmental functions appear to show more dos-
age sensitivity than roles in non-neural tissues (24–27).
Although FOXP4 is the strongest candidate causal gene in the
case identified by Charng and colleagues, additional observa-
tions of FOXP4 disruption are necessary to confirm its etiological
role, particularly since variants in two other genes were also
found in a homozygous state in the child and heterozygous
state in the parents (6).
The precise mechanisms by which FOXP family members
regulate transcription are just beginning to be explored. Several
studies have investigated FOXP2 and FOXP1 target genes in the
brain (28–31) but genes regulated by FOXP4 remain to be discov-
ered. An important mechanism in regulation of gene expression
is that transcription factors act in a combinatorial fashion, and
thus can generate the complex patterns of gene expression
underlying development of the brain and other systems using a
limited set of transcription factors (1,32). The genes regulated by
the FOXP proteins in specific cell types are therefore likely to
depend on the co-expression of other transcription factors.
Indeed, the transcriptional activity of FOXP1, FOXP2 and FOXP4
is regulated by their ability to form homo- and hetero-dimers
with each other through their leucine zipper domain (26). The
three proteins show partially overlapping patterns of expres-
sion in the brain, such that different combinations of
FOXP homo and hetero-dimers may regulate distinct target
genes (33–36).
In addition to dimerization between FOXP family members,
a small number of interactions between FOXP proteins and
other transcription factors have been reported. FOXP1 and
FOXP2 interact with the neural transcription factor TBR1, rare
mutations of which cause ASD accompanied by language defi-
cits (37). Notably, this interaction can be disrupted by etiological
mutations in either FOXP2 or TBR1 (37). Other reported FOXP-
interacting transcription factors include GATAD2B and NKX2.1
(38,39). We hypothesized that there may be further interactions
between FOXPs and other transcription factors with relevance
to physiological developmental processes and neurodevelop-
mental disorders. We therefore sought to identify transcription
factors which may cooperate with FOXP proteins in regulating
gene expression during neurodevelopment, by applying a mass
spectrometry approach. We identified seven novel FOXP-
interacting transcription factors: NR2F1, NR2F2, SATB1, SATB2,
SOX5, YY1 and ZMYM2. Several of these novel interactors have
well-established roles in the development of the nervous sys-
tem and/or are associated with neurodevelopmental disorders.
The interactions with these binding partners involve different
regions of the FOXP2 polypeptide, and are variably affected by
different pathogenic variants in FOXP1 and FOXP2. Thus our
findings provide new clues to the molecular function of the
FOXP proteins, and point to a network of transcription factors
involved in cortical development, disruption of which manifests
as neurodevelopmental disorder.
Results
Identification of FOXP-interacting transcription factors
To identify transcription factors that may cooperate with FOXP
proteins to regulate gene expression, we generated HEK293 cell
lines stably expressing FOXP1, FOXP2 or FOXP4 fused to an N-
terminal FLAG tag. HEK293 cells endogenously express all three
FOXP proteins as well as many other neural genes (40,41). FLAG
affinity-purified protein complexes from these cell lines were
analysed by mass spectrometry (Fig. 1A and B). Three independ-
ent experiments were performed for FOXP1 and FOXP2, and two
experiments for FOXP4. After filtering out non-specific interac-
tors, a total of 381 putative FOXP-interacting proteins were iden-
tified, with substantial overlap between the three FOXP proteins
(Fig. 1C, Supplementary Material, Table S1). For each FOXP pro-
tein, the other two FOXPs were among the interacting proteins
identified in each experiment, reflecting heterodimerization
between FOXP family members (26) (Supplementary Material,
Table S1). Moreover, the set of putative FOXP-interacting pro-
teins included previously reported interaction partners such as
CTBP1, CTBP2 and GATAD2B, confirming that the affinity-purifi-
cation procedure retrieved physiologically relevant FOXP-
interacting proteins (20,38) (Supplementary Material, Table S1).
The transcription factors among the putative FOXP-
interacting proteins were identified, resulting in a set of 28 pro-
teins (Fig. 1C, Table 1, Supplementary Material, Table S2). To pri-
oritize potential interacting transcription factors of most
interest for further investigation, we excluded previously
reported FOXP interactors, and then selected proteins that were
present in two or more replicates, or that had a known
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involvement in neurodevelopmental disorder. Because the
FOXP proteins have high sequence similarity and are likely to
have shared interactors, the appearance of a protein in two
experiments with different FOXPs was treated as a replicate.
We also included transcription factors if two or more members
of the same family of transcription factors were observed
(Supplementary Material, Table S2). This selection resulted in a
filtered list of 12 putative FOXP interactors for follow up.
Validation of interactions between FOXPs and
transcription factors
To validate the selected putative FOXP-interacting transcription
factors, we used a Bioluminescence resonance energy transfer
(BRET) assay. The BRET assay allows protein–protein interactions
to be observed in live cells, and its effectiveness has previously
been shown for successfully confirming interactions between
FOXPs and other proteins (14,20,37,42,43). In the BRET assay, cells
are transfected with a protein of interest fused to Renilla lucifer-
ase, and a candidate interaction partner fused to yellow fluores-
cent protein (YFP). An interaction between the two proteins
under investigation can bring the luciferase and YFP moieties
into sufficient proximity for resonance energy transfer to occur,
causing a shift in the wavelength of the emitted light.
We generated YFP-fusion proteins for the 12 putative FOXP
interactors, and tested them for interaction with luciferase-
fusions of FOXP1, FOXP2 and FOXP4 using the BRET assay. We
detected interactions between FOXP proteins and seven of the
12 putative interactors: SOX5, SATB1, SATB2, NR2F1, NR2F2,
YY1 and ZMYM2 (Fig. 2A and B). In some cases a specific FOXP-
cofactor interaction was detected in the BRET assay that was
not identified in the mass spectrometry screen. For example,
NR2F1, NR2F2 and SATB1 (identified through FOXP4 interactome
screening) interacted with FOXP1 and FOXP2 in the BRET but
had not been detected by mass spectrometry for those two
FOXP proteins (Fig. 2B). This is likely due to the greater sensitiv-
ity of the targeted BRET investigations; these proteins may not
have been detected among the complex mixture of proteins iso-
lated by affinity purification. Transfection of cells with YFP-
fusions of the interactors validated using the BRET assay and
mCherry-FOXP2 showed that all seven interactors exhibited
nuclear localization that completely overlapped with FOXP2
(Fig. 2C). ZMYM2 and SOX5 formed nuclear speckles when
expressed as YFP-fusions, which caused partial redistribution of
co-expressed FOXP2, consistent with the presence of a physical
interaction between ZMYM2/SOX5 and FOXP2 (Fig. 2C).
Five candidate interactors (NFAT5, TFDP1, TP53, ZBTB2 and
ZNF687) did not show evidence of interaction in the BRET assay.
The lack of interaction in this assay was not due to the candi-
date interactors being localized outside the nucleus in live cells,
as all these proteins showed total or partial nuclear localization,
overlapping with that of FOXP2 (Fig. 2C). NFAT5, ZBTB2 and
TFDP1 were present in the cytoplasm, as has been reported pre-
viously, but still showed overlapping expression with FOXP2 in
the nucleus (44,45) (Fig. 2C). The failure to observe an interac-
tion with these proteins in the BRET assay does not exclude that
these proteins might be true FOXP interactors. For a signal to be
detected in the BRET assay, the luciferase and YFP peptides
need to be in close proximity and also must be oriented cor-
rectly so that resonance energy transfer may occur. Therefore,
certain pairs of interactors may not allow for efficiency reso-
nance transfer (46). In addition, the affinity-purification proce-
dure can purify large complexes of proteins, some of which may
interact only indirectly with the bait protein (47,48). Pairs of
Figure 1. Identification of FOXP1-, FOXP2- and FOXP4-interacting proteins. (A) Affinity purifications of FOXP protein complexes using HEK293 cell lines stably expressing
FLAG-FOXP1 (top panel), -FOXP2 (middle panel) and -FOXP4 (bottom panel) protein complexes. FLAG-tagged species were isolated using a FLAG affinity-purification
strategy. Western blots of total lysate (10% Input), washed proteins (wash), and affinity-purified material (elutions) were probed with an anti-FLAG antibody.
(B) Coomassie-stained SDS-polyacrylamide gels of the affinity purifications of FOXP1, FOXP2, FOXP4 and control purification. Arrowheads indicate bands corresponding
to FOXP1, FOXP2 or FOXP4 for each IP. (C) Venn diagram showing the overlaps between the proteins (purple) or transcription factors (light blue) identified in each FOXP
purification.
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proteins that interact indirectly are less likely to produce a sig-
nal in the BRET assay because the interaction-mediating pro-
teins are not overexpressed, and the distance between the
protein pair may also be too great for efficient energy transfer.
Therefore, NFAT5, TFDP1, TP53, ZBTB2 and ZNF687 may have
been isolated by affinity purification due to indirect interaction
with the FOXP bait protein.
Neural transcription factors interact with distinct sites
within FOXP proteins
We next sought to determine which FOXP regions are involved
in the interactions with each of the transcription factors vali-
dated using the BRET assay. Here, we focused on FOXP2, build-
ing on our prior experience with mapping interaction sites
within this particular protein. Specifically, we performed further
BRET assays using a series of synthetic variants of FOXP2 iso-
form I (NM_014491.3, NP_055306.1) truncated at the N- or C-ter-
minus, which have been employed previously to map the
binding sites of FOXP2 interaction partners (Fig. 3A) (20,37,43).
For SOX5 and ZMYM2, an N-terminal FOXP2 fragment contain-
ing residues 1–258 of isoform I retained the ability to interact,
while the counterpart C-terminal fragment (residues 259–715)
did not, indicating that the critical binding determinants for
SOX5 and ZMYM2 lie within the N-terminal 258 residues of
FOXP2 (Fig. 3B and C). In addition, SOX5 and ZMYM2 interacted
with a naturally-occurring alternative FOXP2 isoform (isoform
III) that lacks the N-terminal 92 amino acids of other isoforms
(Supplementary Material, Fig. S1), narrowing down the critical
region to residues 93 to 258. The N-terminal region of FOXP2
also mediates interaction with the transcription factor TBR1,
and with members of the PIAS family of proteins which are
involved in FOXP2 post-translational modification, which sug-
gests that this region may coordinate multiple protein–protein
interactions (37,43). The region includes two polyglutamine
tracts of unknown function that are expanded in FOXP2 relative
to other FOXP family members. Shortening of these tracts to
bring them into line with the sequence of FOXP1 does not affect
interaction with TBR1 or PIAS proteins in cellular assays (37,43).
Tract shortening also did not affect interaction with SOX5 and
ZMYM2 in the current study, as expected given that these pro-
teins also interact with FOXP1 (Supplementary Material, Fig. S2).
Thus, the binding sites for these proteins may lie in the
glutamine-rich regions flanking the polyglutamine tracts.
For the paralogous transcription factors SATB1 and SATB2,
only C-terminally truncated FOXP2 forms containing an intact
forkhead DNA-binding domain retained a full ability to interact
with SATB1/2, suggesting that the interaction requires an intact
forkhead domain together with additional elements from the
N-terminal region of FOXP2 (Fig. 3D). Interestingly, a previous
mass spectrometry study reported SATB1/2 in affinity purifica-
tions of FOXP1 and FOXP3 as well as of FOX proteins from sev-
eral other subfamilies (49). Given that SATBs interact with
diverse FOX proteins that have substantial structural diver-
gence, it is highly likely that the forkhead DNA-binding domain
itself plays an important role in mediating the interaction.
The second pair of paralogous transcription factors in our
screen, NR2F1 and NR2F2, displayed normal interaction with a
FOXP2 form truncated beyond residue 422, but reduced interac-
tion with more severely truncated forms, suggesting a role for the
Table 1. List of candidate FOXP-interacting transcription factors identified in the mass spectrometry screens
Gene symbol Function Associated phenotype
BNC2 Regulation of skin pigmentation
CDC5L Regulation of cell cycle
EMSY DNA repair
FOXC1 Embryonic and ocular development Iris hypoplasia and glaucoma
FOXP1 Brain, heart and lung development ID with language impairment
FOXP2 Brain, heart and lung development Severe language impairment
FOXP4 Brain, heart and lung development Developmental delaya
FUBP1 Regulation of cell cycle
GATAD2B Brain development ID
HIC2 Unknown function
NFAT5 Regulation of inflammatory response
NR2F1 Brain and heart development ID with optic atrophy
NR2F2 Brain and heart development Congenital heart defects
RFX1 Unknown function
SATB1 Regulation of immune system and brain development
SATB2 Brain and bone development ID with language impairment
SOX13 T-cell development
SOX5 Brain and bone development ID with language impairment
TFDP1 Regulation of cell cycle ID with language impairmenta
TOX T-cell development
TP53 Regulation of cell cycle Li-Fraumeni syndrome
YY1 Embryonic development ID
ZBTB2 Regulation of cell cycle
ZBTB39 Unknown function
ZFHX4 Brain and muscle development Ptosis
ZMYM2 Immune system regulation
ZNF148 Unknown function ID with language impairment
ZNF687 Bone development Paget disease of bone
aTentative association.
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region encompassing residues 330–422 (Fig. 3E). Accordingly, nor-
mal interaction was observed with a C-terminal fragment of
FOXP2 beginning at residue 330, whereas a fragment beginning at
residue 423 showed little or no binding (Fig. 3E). Residues 330–422
include a leucine zipper domain which mediates dimerization,
and a zinc finger domain with unknown function. FOXP2
dimerization does not appear to be essential for interaction with
NR2F1/2, because we found that a synthetic dimerization-
deficient FOXP2 variant retained the ability to interact with
NR2F1 (Supplementary Material, Fig. S2D) (26). Interestingly, the
zinc finger domain in FOXP2 contains a short amino acid
sequence (residues 360–367) with high similarity to the NR2 bind-
ing motif F/YSXXLXXL/Y, which has been shown to mediate the
interaction of NR2F1/2 with other transcription factors and co-
repressors (50) (Fig. 3F). This motif is conserved in FOXP1 but not
FOXP4, which could explain why NR2F1/2 interacted with FOXP1
and FOXP2, but not FOXP4, in our BRET assays (Fig. 2A and B) –
the presence of NR2F1/2 in FOXP4 complexes analysed by mass
spectrometry may then be due to an indirect interaction medi-
ated by FOXP1/2.
Figure 2. Validation of identified FOXP-interacting proteins. (A) Bioluminescence resonance energy transfer (BRET) assay for interaction of FOXP1, FOXP2 and FOXP4
variants with the putative FOXP-interacting transcription factors. HEK293 cells were transfected with Renilla luciferase-FOXP1, -FOXP2 or -FOXP4 (donor) and YFP
(acceptor) fusion proteins of the putative FOXP-interacting transcription factors. The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected
BRET ratios6S.E.M (n¼3). (B) Heatmap summarizing the results of the affinity purification followed by mass spectrometry (AP/MS) and the BRET assays. Grey shading
indicates interaction. (C) Fluorescence micrographs of HEK293 cells transfected with YFP-fusions of the putative FOXP-interacting transcription factors, together with
FOXP2 fused to mCherry. Nuclei were stained with Hoechst 33342 (Scale bar¼15 lm).
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Figure 3. Mapping of the regions in FOXP2 that mediate protein–protein interactions (A) Schematic representation of synthetic truncated forms of FOXP2 isoform I
(NM_014491.3, NP_055306.1). Known domains are labeled: glutamine-rich (Q-rich) region (hatched shading) including long and short polyglutamine tracts, zinc finger
(ZF), leucine zipper (LZ), and forkhead domain (FOX). Nuclear localization signals are indicated with red bars. A synthetic nine-residue nuclear targeting sequence
(orange bars) was appended to the C-terminus of variants that lack one or both of the endogenous nuclear localization signals. (B–E, G) BRET assay for interaction of
synthetic truncated FOXP2 variants with FOXP-interacting transcription factors. HEK293 cells were transfected with truncated FOXP2 variants fused to Renilla lucifer-
ase (donor) and SOX5 (B), ZMYM2 (C), SATB1 (D), SATB2 (D), NR2F1 (E), NR2F2 (E) or YY1 (G) fused to YFP (acceptor). The control donor protein is a nuclear-targeted luci-
ferase. Values are mean corrected BRET ratios normalized to full-length FOXP26S.E.M. (n¼3). (F) Schematic representation of FOXP2 showing the putative NRF2
binding motif (light blue bar). The sequence alignment of the region shows the putative NRF2 binding motif in FOXP2 paralogues FOXP1 and FOXP4. Critical residues of
the NRF2 binding motif are shown in bold.
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Finally, in the case of YY1, all of the truncated FOXP2 var-
iants tested retained some degree of interaction, suggesting
that the interaction between FOXP2 and YY1 may involve multi-
ple binding sites (Fig. 3G).
Disorder-related FOXP variants disrupt interactions with
transcription factors
We next investigated etiological variants of FOXP proteins related
to neurodevelopmental disorders, assessing their effects on the
transcription factor interactions that we identified. Heterozygous
disruptions of the FOXP2 gene cause a rare form of speech and
language disorder (22). The disorder was first reported in a three-
generation family, in which all of the affected members carry the
FOXP2 variant p.R553H, which is unable to bind to its typical DNA
target sequence (15,51). Several other variants in FOXP2 have
since been reported in individuals with neurodevelopmental dis-
orders; functional studies indicate that some of these are etiologi-
cal variants whereas others are benign rare variants (Fig. 4A)
(16–21). Etiological variants had been shown to severely disrupt
core molecular aspects of FOXP2 protein function, such as tran-
scriptional activity and subcellular localization (43). Using the
BRET assay, we examined the effects of seven rare variants on
the interaction of FOXP2 with the transcription factors identified
in our interactor screen (Fig. 4B–H). Four of these seven rare var-
iants had been shown to be benign in prior cellular assays (43).
All four of these benign rare variants displayed normal interac-
tion with the novel interaction partners, whereas almost all inter-
actions involving one of the three pathogenic FOXP2 variants
were either abolished or disrupted (Fig. 4B–I).
Heterozygous mutations of the FOXP1 gene result in a neuro-
developmental syndrome characterized by mild to moderate ID
with features of ASD and speech and language impairments
(13,14). We examined the effects of seven etiological variants of
FOXP1 on interactions with the six FOXP1-interacting transcrip-
tion factors identified in our screen. The etiological FOXP1 var-
iants comprised four truncated and three missense variants.
The truncated variants did not interact with any of the tran-
scription factors tested in our assays, whereas two of the three
missense variants retained some degree of interaction with one
or more interaction partner (Fig. 5B–H). The FOXP1 missense
variants p.R465G and p.R514C retained the ability to interact
with SOX5 (Fig. 5B). Accordingly, co-expression of these variants
with SOX5 led to mislocalization of SOX5 into the nuclear aggre-
gates formed by the abnormal FOXP1 proteins, an effect not
observed when SOX5 was co-expressed with other FOXP1 var-
iants (Fig. 5I). Thus, most etiological FOXP1 and FOXP2 variants
represent a loss of function with respect to interaction with
other neural transcription factors. However the FOXP1 p.R465G
and p.R514C variants may exert dominant-negative effects
in vivo by interfering with the function of interacting transcrip-
tion factors such as SOX5. Such differences in the behaviour of
different protein variants have the potential to contribute to
phenotypic variation observed between individuals with
FOXP1-related disorder (14).
FOXP2 is co-expressed with interacting transcription
factors in specific neuronal subpopulations
We sought to identify the cell types in which the newly identified
interactions between FOXP2 and transcription factors may be
physiologically relevant. Of the seven FOXP-interacting transcrip-
tion factors validated using the BRET assay, ZMYM2 and YY1 are
ubiquitously expressed, while SOX5, SATB1, SATB2, NR2F1 and
NR2F2 are all neural transcription factors that are expressed in
subsets of neurons within the cerebral cortex (52–55). We there-
fore examined the co-localization of Foxp2 with the interacting
neural transcription factors in mouse brain by immunostaining
(Fig. 6). Brains frommice at postnatal day 3 were used because by
this point in development the cortical layers have formed and
layer-specific Foxp2 expression can readily be detected (35).
Foxp2 was observed in the deep layers of the cortex, as well as in
the striatum, as previously reported (Fig. 6) (35). Each of the five
neural transcription factors showed a different pattern of expres-
sion in the cortex. Sox5 exhibited extensive co-expression with
Foxp2 in deep layer cortical neurons (Fig. 6). Satb2 expression was
found throughout all the six layers of the cortex and its expres-
sion coincided with Foxp2 in a subpopulation of neurons of layer
V (Fig. 6). Satb1 was detected in layers IV to VI, including a subpo-
pulation of Foxp2-expressing cells (Fig. 6). Nr2f1 was expressed in
all the layers of the cortex, including the vast majority of Foxp2-
positive cells in layers V and VI (Fig. 6). In contrast, and despite
being expressed in a few scattered cells in the cortex layers I, IV
and V, Nr2f2 was not co-expressed with Foxp2 in any cortical
neurons (Fig. 6). However, Nr2f2 was found to be extensively co-
expressed with Foxp2 in the Purkinje cells of the cerebellum,
another key neuronal subtype with high Foxp2 expression (Fig. 7).
These data are consistent with the prevailing view that expres-
sion of different combinations of transcription factors is essential
to determining andmaintaining cell identity and function.
Discussion
In this study, through mass spectrometry-based proteomics
followed by targeted analysis using BRET, we identified and
characterized the interactions between FOXP family proteins
and seven neurally-expressed transcription factors. We
demonstrated co-expression of the interactors with Foxp2 in
functionally-relevant neuronal subtypes in the early postnatal
mouse brain, confirming that the reported interactions are of
potential physiological significance in vivo. We found that differ-
ent interaction partners have distinct binding sites within the
FOXP2 protein, and that disorder-associated variants in FOXP1
and FOXP2 generally cause broad disruption of protein–protein
interactions, but in some cases may lead to a dominant-
negative effect in which abnormal FOXP protein may interfere
with the functions of a normal interactor.
The interaction partners we identified have important, yet
diverse, roles in neurodevelopment. Sox5 is expressed in deep
cortical layers during embryonic and early postnatal stages and
controls timing of the generation of distinct corticofugal neuron
subtypes (52). Loss of Sox5 results in aberrant differentiation
and abnormal migration of cortical projection neurons (52).
Satb2 is a key regulator of cortical development and is
expressed throughout all cortical layers (53,56). The neural func-
tions of Satb1 have not been as extensively investigated as its
roles in the immune system (57), but it is reported to regulate
development of cortical interneurons and facilitate cortical neu-
ron plasticity by modulating dendritic spine density (58,59).
Nr2f1 regulates the differentiation of motor neurons, axonal
projection and cortical arealization and, together with Nr2f2,
plays a role in cell migration and regulation of neurogenesis
(55,60–63). The interactions we demonstrated between these
proteins and FOXP family members may therefore impact on a
range of crucial processes in cortical development and matura-
tion. Protein–protein interactions and their downstream conse-
quences are naturally limited to the cell populations in which
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Figure 4. Etiological mutations in FOXP2 disrupt protein interactions (A) Schematic representation of the FOXP2 protein isoform I (NM_014491.3, NP_055306.1) showing
rare variants found in individuals with neurodevelopmental disorders. Pathogenic variants are shown in red and benign variants in black. Known domains are labeled:
glutamine-rich (Q-rich) region (hatched shading), long (QL) and short (QS) polyglutamine tracts, zinc finger (ZF), leucine zipper (LZ) and forkhead domain (FOX). Nuclear
localization signals are indicated with red bars. (B–H) BRET assays for interaction of FOXP2 variants with FOXP-interacting proteins. HEK293 cells were transfected with
Renilla luciferase-FOXP2 wild type (WT) or variants (donor) and YFP (acceptor) fusions of SOX5 (B), SATB1 (C), SATB2 (D), NR2F1 (E), NR2F2 (F), YY1 (G) or ZMYM2 (H).
The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET ratios normalized to wild-type FOXP26S.E.M. (n¼3). (I) Heatmap summarizing
the results of the BRET assays between FOXP2 variants and the FOXP-interacting transcription factors. White squares indicate an unaffected interaction; a hatched pat-
tern, a reduced interaction; and grey shading, a severely reduced interaction.
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the proteins are co-expressed. Our analysis of co-expression of
Foxp2 and interacting transcription factors in early postnatal
mouse cortex shows that the subpopulations of co-expressing
cells vary from a minor fraction of cells to the majority of deep
layer projection neurons. Foxp1 and Foxp4 show different pat-
terns of expression in the developing cortex compared with
Foxp2, leading to further combinations of protein–protein inter-
actions with differing functional outcomes.
In addition to roles in cortical development, our findings
highlight potential interactions in the cerebellum. We found co-
expression of Nr2f2 and Foxp2 in Purkinje cells of the cerebel-
lum; expression of the individual proteins in Purkinje cells has
been reported previously in separate studies (34,35,54). Nr2f2
regulates cerebellar growth and patterning (54), while Foxp2 has
been implicated in dendritic outgrowth and arborization of
Purkinje cells (64) and mice lacking functional Foxp2 have small
cerebellums (65). Foxp4, which is similarly expressed in
Purkinje cells, may also be involved in the maintenance of den-
dritic arborization (66).
FOXP1, FOXP2 and FOXP4 have all been implicated in human
genetic disorders with neurodevelopmental phenotypes.
Several of the FOXP-interacting transcription factors identified
in this study are known to cause neurodevelopmental disorders
through haploinsufficiency. SOX5 haploinsufficiency results in
ID and language impairment (OMIM #616803) (67,68). De novo
mutations in SATB2 cause syndromic ID, usually with absent or
near absent speech, and often cleft palate or dental anomalies
(OMIM #612313) (69–71). Mutations in NR2F1 cause Bosch-
Boonstra-Schaaf optic atrophy syndrome, a dominant disorder
characterized by optic atrophy and ID, frequently accompanied
by hypotonia, seizures, ASD and oromotor dysfunction (OMIM
#615722) (72,73). YY1 haploinsufficiency leads to a syndrome
that includes ID often accompanied by motor problems and var-
ious congenital malformations (OMIM #617557) (74,75). ZMYM2
de novo mutations have been found in large-scale exome
sequencing studies of cases of ASD (76). However, since ZMYM2
is ubiquitously expressed, further cases of disruptions are
needed in order to confidently establish its involvement in neu-
rodevelopmental disorders. Of note, following completion of
experiments for this study, recurrent de novo mutations in
ZNF148, another transcription factor identified in our mass
spectrometry screen, have been identified in individuals with
developmental delay and ID (OMIM #617260) (77). The differing
levels of ID and speech/language impairment associated with
disruption of FOXP proteins and their interacting transcription
factors suggests that reduced levels of these transcription fac-
tors lead to differing, but potentially related, disturbances in
downstream gene expression and cortical development.
Most of the identified FOXP-interacting transcription factors
control cortical development in an interconnected fashion,
cooperating with each other but also forming positive and nega-
tive loops of regulation between them (78). For instance, to
maintain the specific neuronal identities in deeper layers of the
cortex, SOX5 directly represses Fezf2, a key node of the cortical
transcriptional network, in layer VI and the subplate (79), which
at the same time is repressed by TBR1 (80), an ASD-related tran-
scription factor also known to interact with FOXP2 and FOXP1
(37). In contrast, in layer V, SATB2 promotes the expression of
SOX5 and Fezf2, while Fezf2 represses SATB2 (81). Also, NR2F1,
SATB2 and SOX5 control the development of cortical projection
neurons at least in part by repressing the same target gene,
encoding the transcription factor BCL11B (52,63,82,83).
Strikingly, NR2F1 and NR2F2 physically interact with transcrip-
tion factors BCL11B and BCL11A (50), which also plays roles in
cortical development by repressing TBR1 (84). BCL11A haploin-
sufficiency has recently been identified as a cause of sporadic ID
(85). Therefore, a number of genetically-distinct neurodevelop-
mental disorders may have shared roots in this complex regula-
tory network of transcription factors that orchestrates cortical
development, and our results contribute to extend the charac-
terization of this network. It will be interesting in the future to
further determine the specific roles the FOXPs play in this net-
work and, in general, better understand the transcriptional
architecture underlying cortical development.
Clearly the proteins investigated here are only a subset of the
biologically-important interactors of FOXP proteins. Our mass
spectrometry screens provide the largest list of candidate FOXP-
interacting proteins reported to date, and represent a resource for
further investigation of protein networks surrounding these tran-
scription factors. We elected to focus on transcription factors
with potential roles in neurodevelopment, and a logical next step
would be to consider proteins mediating transcription factor
activity, such as chromatin modifying and remodelling com-
plexes. For example, the candidate FOXP-interacting proteins
include the chromatin remodeler SETD2, haploinsufficiency of
which leads to Luscan-Lumish syndrome (OMIM #616831), a neu-
rodevelopmental disorder characterized by ID and macrocephaly
accompanied by speech delay (86,87). In addition, FOXP proteins
have roles in multiple tissues and candidate interactors in our
screen may be of relevance to the function of FOXPs in non-
neuronal contexts. For example, FOXP1, FOXP2 and FOXP4 are all
expressed in the embryonic heart, and mice lacking Foxp1 or
Foxp4 die before birth due to heart defects (8,35,88,89).
Heterozygous mutations in our confirmed FOXP-interaction tran-
scription factor NR2F2 cause a variety of congenital heart defects
(90), and a critical role in heart development has also been
described for our confirmed interactor YY1 (91). Therefore, the
FOXPs may cooperate with NR2F2 and YY1 to regulate down-
stream target genes important for cardiac development.
Our strategy employed affinity purification coupled to mass
spectrometry to screen for potential FOXP-interacting transcrip-
tion factors, followed by validation of selected candidate inter-
actors using a BRET assay. These two methods have different
strengths in relation to identifying protein interaction partners.
The affinity-purification method gives a proteome-wide picture
of protein interactions, but may miss weak or transient interac-
tions because it is performed on cell lysates, and may suffer
from false positives due to non-specific and indirect interac-
tions. In contrast, BRET is a targeted method which monitors
protein interactions in living cells, can detect transient interac-
tions, is less vulnerable to false positives, but may give false
negatives due to the constraints on energy transfer (42). We
show here that this two-stage approach is effective in identify-
ing high-confidence protein interaction partners with potential
biological importance.
In conclusion, our findings situate the FOXPs within a
broader molecular network that orchestrates cortical develop-
ment, and thus provide novel clues as to how these proteins
work to build a functioning brain, and why their deficiency
leads to neurodevelopmental disorders.
Materials and Methods
DNA constructs
The cloning of human FOXP2 (NM_014491), FOXP1 (NM_032682),
FOXP4 (NM_001012426), has been described previously (20). The
coding sequences of TFDP1 (NM_007111), NR2F1 (NM_005654),
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Figure 5. Etiological mutations in FOXP1 disrupt protein interactions. (A) Schematic representation of the FOXP1 protein (NM_032682, NP_116071) showing rare variants
found in individuals with neurodevelopmental disorders. Known domains are labeled: glutamine-rich (Q-rich) region (hatched shading), zinc finger (ZF), leucine zipper
(LZ) and forkhead domain (FOX). Nuclear localization signals are indicated with red bars. (B–G) BRET assays for interaction of FOXP1 variants with the FOXP-interacting
proteins. HEK293 cells were transfected with Renilla luciferase-FOXP1 wild type (WT) or variants (donor) and YFP (acceptor) fusions of SOX5 (B), SATB1 (C), NR2F1 (D),
NR2F2 (E), YY1 (F) or ZMYM2 (G). The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET ratios normalized to wild-type FOXP16S.E.M.
(n¼3). (H) Heatmap summarizing the results of the BRET assays between FOXP2 variants and the FOXP-interacting transcription factors. White squares indicate an
unaffected interaction; a hatched pattern, a reduced interaction; and grey shading, a severely reduced interaction. (I) Fluorescence micrographs of HEK293 cells trans-
fected with YFP-fusions of FOXP1 wild-type or etiological variants, together with SOX5 fused to mCherry. Nuclei were stained with Hoechst 33342. (Scale bar¼ 15 lm).
1221Human Molecular Genetics, 2018, Vol. 27, No. 7 |
Downloaded from https://academic.oup.com/hmg/article-abstract/27/7/1212/4819278
by Erasmus Universiteit Rotterdam user
on 16 April 2018
Figure 6. Foxp2 is co-expressed with Sox5, Satb1, Satb2 and Nr2f2 in the cerebral cortex. (A) Immunofluorescence experiments to assess endogenous co-expression of
Sox5, Satb1, Satb2, Nr2f1 and Nr2f2 with Foxp2 in the cerebral cortex of P3 mice brains. A white line indicates the cerebral cortex, layer numbers are indicated. A dashed
white line demarks the striatum (str) (scale bar¼200 lm) (B) Magnified views of the region indicated with a white square in (A). White arrows indicate cells that co-
express both Foxp2 and the Foxp2-interacting transcription factor (Scale bar¼50 lm). For (A) and (B), Foxp2 protein expression is shown in red; Foxp2-interacting pro-
teins, in green; and nuclei stained with DAPI, in blue.
Figure 7. Foxp2 is co-expressed with Nr2f2 in the Purkinje cells in the cerebellum. Immunofluorescence experiments to assess endogenous co-expression of Nr2f2 with
Foxp2 in the cerebellum of P3 mice brains. Foxp2 protein expression is shown in red; Nr2f2, in green; and nuclei stained with DAPI, in blue. (Scale bar¼200 lm).
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NR2F2 (NM_021005), SATB1 (NM_002971), SATB2 (NM_001172509),
ZBTB2 (NM_020861), TP53 (NM_000546), ZNF687 (NM_001304763),
ZMYM2 (NM_003453), NFAT5 (NM_138714), YY1 (NM_003403) and
SOX5 (NM_001330785) were amplified using the primers listed in
Supplementary Material, Table S3 and cloned into pCR2.1-TOPO.
Human fetal brain cDNA was used as template for PCR, except in
the cases of NR2F2 and NFAT5, which were amplified from the
plasmids pAAV-hNR2F2-RFP (Addgene, #22926) and pEGFP-
NFAT5 (Addgene, #13627), respectively. The cloning of FOXP2 var-
iants p.Q17L, p.M406T, p.P416T, p.R553H, p.N597H, p.R328*,
P.Q390Vfs*7, of synthetic truncated forms of FOXP2, and of FOXP1
variants p.A339Sfs*4, p.V423Hfs*37, p.Y439*, p.R465G, p.R514C,
p.R252*, and p.W534R has been described previously (14,20). For
expression of FLAG-tagged protein for affinity purification, the
coding regions of FOXP1, FOXP2 and FOXP4 were subcloned
into the pEF1aFLAGbio expression vector, provided by Dr. J.W.
Wang (92). For expression of fusion proteins with Renilla lucifer-
ase, YFP and mCherry tags, cDNAs were subcloned into the pLuc,
pYFP, and pmCherry expression vectors, respectively, which
have been described previously (20,42). To generate the nuclear-
targeted Renilla luciferase and YFP control plasmids used in the
BRET assay, a peptide including the nuclear localization signal of
the SV40 large T antigen (CGYGPKKKRKVGGLDN) was appended
into the C-terminus of the pLuc and pYFP plasmids by ligating
synthetic double-stranded oligonucleotides between the BamHI
and XbaI sites of the pLuc and pYFP vectors (42). Addition of this
signal causes a significant redistribution of protein to the nucleus,
as previously reported in (42). All constructs were verified by
Sanger sequencing.
Cell culture and transfection
HEK293 cells were obtained from ECACC (cat. No. 85120602) and
cultured in DMEM supplemented with 10% fetal bovine serum.
Transient transfections were performed using GeneJuice
(Merck-Millipore) according to the manufacturer’s instructions.
To generate stable cell lines expressing FLAG-tagged FOXP pro-
teins, HEK293 cells were transfected with pEF1aFLAGbio con-
taining the coding sequence of FOXP1, FOXP2, or FOXP4 using
GeneJuice (Merck-Millipore) according to the manufacturer’s
instructions. Single clones were isolated following selection
with culture medium containing 10 mM puromycin. Expression
of the tagged proteins in selected clones was confirmed by west-
ern blotting of cell lysates using anti-FLAG antibody (Sigma).
Selected stable cell lines were maintained in DMEM supple-
mented with 10% fetal bovine serum and 5 mM puromycin.
Affinity purification and mass spectrometry (AP/MS)
HEK293 cell lines stably expressing FLAG-tagged FOXP1, FOXP2
or FOXP4, or control cell lines, were expanded to twenty 15 cm
dishes, washed with PBS, and harvested by scraping. The
affinity-purification procedure has been described previously
(93). Briefly, nuclear extracts were dialysed into buffer C-100 (20
mM HEPES pH 7.6, 0.2 mM EDTA, 1.5 mM MgCl2, 100 mM KCl,
20% glycerol) and then incubated with anti-FLAG M2 agarose
beads (Sigma) and benzonase (Novagen) for 3 h at 4C. Beads
were washed five times for 5 min with buffer C-100 containing
0.02% NP-40 (C-100*) and bound proteins were eluted four times
for 15 min at 4C with buffer C-100* containing 0.2 mg/ml FLAG-
tripeptide (Sigma). The purification of FOXP1, FOXP2 or FOXP4
was checked by western blot using anti-FLAG antibody. The elu-
tion fractions were pooled and proteins were TCA-precipitated,
resolved by SDS-polyacrylamide gel electrophoresis, stained
with Colloidal Blue Staining Kit (Invitrogen) and analysed by
mass spectrometry as described previously (93–96).
Mass-spectrometry analyses were performed on three
independent purifications from FOXP1- and FOXP2-expressing
cell lines, and two independent purifications from FOXP4-
expressing cell lines. Each purification was performed in paral-
lel with stable cell lines transfected with empty control vector.
To remove non-specific interactors, peptide lists were filtered
using peptides found in the control conditions or in the
CRAPome database, a collection of common contaminants in
AP/MS data (97). Proteins with a Mascot score lower than 45
were also excluded.
Western blotting
Proteins from cell lysates were resolved on 10% SDS-
polyacrylamide gels and transferred to PVDF membranes using
a TransBlot Turbo Blotting apparatus (Bio-Rad). Membranes
were blocked in PBS containing 5% milk and 0.1% Tween-20 and
incubated overnight at 4C with primary antibody. After wash-
ing, membranes were incubated with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit IgG for 45 min at
room temperature. Proteins were visualized using Novex ECL
Chemiluminescent Substrate Reagent Kit (Invitrogen) and a
ChemiDoc XRSþ imaging system (Bio-Rad).
BRET assay
BRET assays were performed as described previously (42).
Briefly, HEK293 cells were transfected in 96-well plates with
plasmids encoding YFP- and luciferase-fusion proteins. After
36–48 h, Enduren live cell luciferase substrate (Promega) was
added at a final concentration of 60 mM. Cells were cultured for a
further 4 h, and emission readings (integrated over 10 s)
were taken using a TECAN F200PRO microplate reader using the
Blue1 and Green1 filter sets. Expression levels of the YFP-fusion
proteins were measured by taking fluorescent readings
using the filter set and dichroic mirror suitable for green
fluorescent protein (excitation 480 nm, emission 535 nm).
The corrected BRET ratio was calculated with the following
formula: [Green1(experimental condition)/Blue1(experimental condition)]-
[Green1(control condition)/Blue1(control condition)]. The control condi-
tions used luciferase or YFP fused to a C-terminal nuclear local-
ization signal (42).
Fluorescence microscopy
HEK293 cells were seeded on coverslips coated with poly-L-
lysine. Cells were transfected with plasmids encoding proteins
of interest fused to YFP or mCherry. Cells were cultured for 30 h
post-transfection, and then fixed with 4% paraformaldehyde.
Nuclei were stained with Hoechst 33342. Fluorescence images
were acquired using an Axiovert A-1 fluorescent microscope
with ZEN Image software (Zeiss).
Immunofluorescence
Immunofluorescence experiments were performed on mouse
brain sections at postnatal day 3 (P3). Brains were harvested
and embedded in optimal cutting temperature (OCT) compound
on dry ice. Sagittal sections were prepared at a thickness of
4 mm using a Leica CM1950 cryostat and then preserved at
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20C. Tissue sections were fixed in ice-cold acetone for 10 min
at 20C, blocked using 10% donkey serum in PBS for 1 h at
room temperature, and incubated overnight at 4C with primary
antibody diluted in 2% donkey serum. The following antibodies
were used: goat anti-FOXP2 N-16 antibody (sc-21069, Santa
Cruz), rabbit anti-FOXP2 antibody (ab16046, Abcam), rabbit anti-
SOX5 (ab94396, Abcam), goat anti-SATB1 E-15 antibody (sc-5990,
Santa Cruz), rabbit anti-SATB2 antibody (ab34735, Abcam), rab-
bit anti-NR2F1 (ab181137, Abcam) and rabbit anti-NR2F2
(ab42672, Abcam). After washing, tissue sections were incu-
bated with fluorescently-labeled secondary antibodies diluted
in 2% donkey serum: donkey anti-rabbit IgG Alexa488 (a21206,
Invitrogen) and donkey anti-goat IgG Alexa594 (a11058,
Invitrogen). Slides were mounted with VectaShield Antifade
Mounting Medium with DAPI (Vector Labs) and then imaged
using Axiovert A-1 fluorescent microscope with ZEN Image soft-
ware (Zeiss).
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We wish to thank Svenja Idel for help generating DNA
constructs.
Conflict of Interest statement. The authors declare that they have
no conflict of interests.
Funding
Max Planck Society.
References
1. Silbereis, J.C., Pochareddy, S., Zhu, Y., Li, M. and Sestan, N.
(2016) The cellular andmolecular landscapes of the develop-
ing human central nervous system. Neuron, 89, 248–268.
2. De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha,
K., Cicek, A.E., Kou, Y., Liu, L., Fromer, M., Walker, S. et al.
(2014) Synaptic, transcriptional and chromatin genes dis-
rupted in autism.Nature, 515, 209–215.
3. Kwan, K.Y. (2013) Transcriptional dysregulation of neocorti-
cal circuit assembly in ASD. Int. Rev. Neurobiol., 113, 167–205.
4. Peter, B., Matsushita, M., Oda, K. and Raskind, W. (2014) De
novo microdeletion of BCL11A is associated with severe
speech sound disorder. Am. J. Med. Genet. A, 164A, 2091–2096.
5. Bowers, J.M. and Konopka, G. (2012) The role of the FOXP
family of transcription factors in ASD. Dis. Markers, 33,
251–260.
6. Charng, W.-L., Karaca, E., Coban Akdemir, Z., Gambin, T.,
Atik, M.M., Gu, S., Posey, J.E., Jhangiani, S.N., Muzny, D.M.,
Doddapaneni, H. et al. (2016) Exome sequencing in mostly
consanguineous Arab families with neurologic disease pro-
vides a high potential molecular diagnosis rate. BMC Med.
Genomics, 9, 42.
7. Shu, W., Yang, H., Zhang, L., Lu, M.M. and Morrisey, E.E.
(2001) Characterization of a new subfamily of
winged-helix/forkhead (Fox) genes that are expressed in the
lung and act as transcriptional repressors. J. Biol. Chem., 276,
27488–27497.
8. Teufel, A., Wong, E.A., Mukhopadhyay, M., Malik, N. and
Westphal, H. (2003) FoxP4, a novel forkhead transcription
factor. Biochim. Biophys. Acta, 1627, 147–152.
9. Fontenot, J.D., Gavin, M.A. and Rudensky, A.Y. (2003) Foxp3
programs the development and function of CD4þCD25þ reg-
ulatory T cells. Nat. Immunol., 4, 330–336.
10. Hamdan, F.F., Daoud, H., Rochefort, D., Piton, A., Gauthier, J.,
Langlois, M., Foomani, G., Dobrzeniecka, S., Krebs, M.-O.,
Joober, R. et al. (2010) De novo mutations in FOXP1 in cases
with intellectual disability, autism, and language impair-
ment. Am. J. Hum. Genet., 87, 671–678.
11. O’Roak, B.J., Deriziotis, P., Lee, C., Vives, L., Schwartz, J.J.,
Girirajan, S., Karakoc, E., Mackenzie, A.P., Ng, S.B., Baker, C.
et al. (2011) Exome sequencing in sporadic autism spectrum
disorders identifies severe de novo mutations. Nat. Genet.,
43, 585–589.
12. Srivastava, S., Cohen, J.S., Vernon, H., Bara~nano, K.,
McClellan, R., Jamal, L., Naidu, S. and Fatemi, A. (2014)
Clinical whole exome sequencing in child neurology prac-
tice.Ann. Neurol., 76, 473–483.
13. Lozano, R., Vino, A., Lozano, C., Fisher, S.E. and Deriziotis, P.
(2015) A de novo FOXP1 variant in a patient with autism,
intellectual disability and severe speech and language
impairment. Eur. J. Hum. Genet., 23, 1702–1707.
14. Sollis, E., Graham, S.A., Vino, A., Froehlich, H., Vreeburg, M.,
Dimitropoulou, D., Gilissen, C., Pfundt, R., Rappold, G.A.,
Brunner, H.G. et al. (2016) Identification and functional char-
acterization of de novo FOXP1 variants provides novel
insights into the etiology of neurodevelopmental disorder.
Hum. Mol. Genet., 25, 546–557.
15. Lai, C.S., Fisher, S.E., Hurst, J.A., Vargha-Khadem, F. and
Monaco, A.P. (2001) A forkhead-domain gene is mutated in a
severe speech and language disorder. Nature, 413, 519–523.
16. MacDermot, K.D., Bonora, E., Sykes, N., Coupe, A.-M., Lai,
C.S.L., Vernes, S.C., Vargha-Khadem, F., McKenzie, F., Smith,
R.L., Monaco, A.P. et al. (2005) Identification of FOXP2 trunca-
tion as a novel cause of developmental speech and language
deficits.Am. J. Hum. Genet., 76, 1074–1080.
17. Roll, P., Vernes, S.C., Bruneau, N., Cillario, J., Ponsole-
Lenfant, M., Massacrier, A., Rudolf, G., Khalife, M., Hirsch, E.,
Fisher, S.E. et al. (2010) Molecular networks implicated in
speech-related disorders: FOXP2 regulates the SRPX2/uPAR
complex.Hum. Mol. Genet., 19, 4848–4860.
18. Laffin, J.J.S., Raca, G., Jackson, C.A., Strand, E.A., Jakielski, K.J.
and Shriberg, L.D. (2012) Novel candidate genes and regions
for childhood apraxia of speech identified by array compara-
tive genomic hybridization. Genet. Med., 14, 928–936.
19. Turner, S.J., Hildebrand, M.S., Block, S., Damiano, J., Fahey,
M., Reilly, S., Bahlo, M., Scheffer, I.E. and Morgan, A.T. (2013)
Small intragenic deletion in FOXP2 associated with child-
hood apraxia of speech and dysarthria. Am. J. Med. Genet. A,
161, 2321–2326.
20. Estruch, S.B., Graham, S.A., Deriziotis, P. and Fisher, S.E.
(2016) The language-related transcription factor FOXP2 is
post-translationally modified with small ubiquitin-like
modifiers. Sci. Rep., 6, 20911.
21. Reuter, M.S., Riess, A., Moog, U., Briggs, T.A., Chandler, K.E.,
Rauch, A., Stampfer, M., Steindl, K., Gla¨ser, D., Joset, P. et al.
(2016) FOXP2 variants in 14 individuals with developmental
speech and language disorders broaden the mutational and
clinical spectrum. J. Med. Genet., 54, 64–72.
22. Graham, S.A. and Fisher, S.E. (2015) Understanding
Language from a Genomic Perspective. Annu. Rev. Genet., 49,
131–160.
1224 | Human Molecular Genetics, 2018, Vol. 27, No. 7
Downloaded from https://academic.oup.com/hmg/article-abstract/27/7/1212/4819278
by Erasmus Universiteit Rotterdam user
on 16 April 2018
23. Bacon, C. and Rappold, G.A. (2012) The distinct and overlap-
ping phenotypic spectra of FOXP1 and FOXP2 in cognitive
disorders. Hum. Genet., 131, 1687–1698.
24. Shu, W., Cho, J.Y., Jiang, Y., Zhang, M., Weisz, D., Elder, G.A.,
Schmeidler, J., De Gasperi, R., Sosa, M.A.G., Rabidou, D. et al.
(2005) Altered ultrasonic vocalization in mice with a disrup-
tion in the Foxp2 gene. Proc. Natl. Acad. Sci. U.S.A, 102,
9643–9648.
25. Shu, W., Lu, M.M., Zhang, Y., Tucker, P.W., Zhou, D. and
Morrisey, E.E. (2007) Foxp2 and Foxp1 cooperatively regulate
lung and esophagus development. Development, 134,
1991–2000.
26. Li, S., Weidenfeld, J. and Morrisey, E.E. (2004) Transcriptional
and DNA binding activity of the Foxp1/2/4 family is modu-
lated by heterotypic and homotypic protein interactions.
Mol. Cell. Biol., 24, 809–822.
27. Li, X., Xiao, J., Fro¨hlich, H., Tu, X., Li, L., Xu, Y., Cao, H., Qu, J.,
Rappold, G.A., Chen, J.-G. and Sato, M. (2015) Foxp1 regulates
cortical radial migration and neuronal morphogenesis
in developing cerebral cortex. PLoS ONE, 10,
e0127671–e0127619.
28. Spiteri, E., Konopka, G., Coppola, G., Bomar, J., Oldham, M.,
Ou, J., Vernes, S.C., Fisher, S.E., Ren, B. and Geschwind, D.H.
(2007) Identification of the transcriptional targets of FOXP2,
a gene linked to speech and language, in developing human
brain. Am. J. Hum. Genet., 81, 1144–1157.
29. Vernes, S.C., Spiteri, E., Nicod, J., Groszer, M., Taylor, J.M.,
Davies, K.E., Geschwind, D.H. and Fisher, S.E. (2007)
High-throughput analysis of promoter occupancy reveals
direct neural targets of FOXP2, a genemutated in speech and
language disorders. Am. J. Hum. Genet., 81, 1232–1250.
30. Vernes, S.C., Oliver, P.L., Spiteri, E., Lockstone, H.E., Puliyadi,
R., Taylor, J.M., Ho, J., Mombereau, C., Brewer, A. and Lowy, E.
(2011) Foxp2 regulates gene networks implicated in neurite
outgrowth in the developing brain. PLoS Genet., 7, 1–17.
31. Araujo, D.J., Anderson, A.G., Berto, S., Runnels, W., Harper,
M., Ammanuel, S., Rieger, M.A., Huang, H.-C., Rajkovich, K.,
Loerwald, K.W. et al. (2015) FoxP1 orchestration of
ASD-relevant signaling pathways in the striatum. Genes
Dev., 29, 2081–2096.
32. Smith, N.C. and Matthews, J.M. (2016) Mechanisms of
DNA-binding specificity and functional gene regulation by
transcription factors. Curr. Opin. Struct. Biol., 38, 68–74.
33. Takahashi, K., Liu, F.-C., Hirokawa, K. and Takahashi, H.
(2008) Expression of Foxp4 in the developing and adult rat
forebrain. J. Neurosci. Res., 86, 3106–3116.
34. Lai, C.S.L., Gerrelli, D., Monaco, A.P., Fisher, S.E. and Copp,
A.J. (2003) FOXP2 expression during brain development coin-
cides with adult sites of pathology in a severe speech and
language disorder. Brain, 126, 2455–2462.
35. Ferland, R.J., Cherry, T.J., Preware, P.O., Morrisey, E.E. and
Walsh, C.A. (2003) Characterization of Foxp2 and Foxp1
mRNA and protein in the developing and mature brain. J.
Comp. Neurol., 460, 266–279.
36. Sin, C., Li, H. and Crawford, D.A. (2015) Transcriptional regu-
lation by FOXP1, FOXP2, and FOXP4 dimerization. J. Mol.
Neurosci., 55, 437–448.
37. Deriziotis, P., O’Roak, B.J., Graham, S.A., Estruch, S.B.,
Dimitropoulou, D., Bernier, R.A., Gerdts, J., Shendure, J.,
Eichler, E.E. and Fisher, S.E. (2014) De novo TBR1 mutations
in sporadic autism disrupt protein functions. Nat. Commun.,
5, 4954.
38. Chokas, A.L., Trivedi, C.M., Lu, M.M., Tucker, P.W., Li, S.,
Epstein, J.A. and Morrisey, E.E. (2010) Foxp1/2/4-NuRD
interactions regulate gene expression and epithelial injury
response in the lung via regulation of interleukin-6. J. Biol.
Chem., 285, 13304–13313.
39. Zhou, B., Zhong, Q., Minoo, P., Li, C., Ann, D.K., Frenkel, B.,
Morrisey, E.E., Crandall, E.D. and Borok, Z. (2008) Foxp2
inhibits Nkx2.1-mediated transcription of SP-C via interac-
tions with the Nkx2.1 homeodomain. Am. J. Respir. Cell Mol.
Biol., 38, 750–758.
40. Shaw, G., Morse, S., Ararat, M. and Graham, F.L. (2002)
Preferential transformation of human neuronal cells
by human adenoviruses and the origin of HEK 293 cells.
FASEB J., 16, 869–871.
41. Stepanenko, A.A. and Dmitrenko, V.V. (2015) HEK293 in cell
biology and cancer research: phenotype, karyotype, tumori-
genicity, and stress-induced genome-phenotype evolution.
Gene, 569, 182–190.
42. Deriziotis, P., Graham, S.A., Estruch, S.B. and Fisher, S.E.
(2014) Investigating protein–protein interactions in live cells
using bioluminescence resonance energy transfer. J. Vis.
Exp., 10.3791/51438.
43. Estruch, S.B., Graham, S.A., Chinnappa, S.M., Deriziotis, P.
and Fisher, S.E. (2016) Functional characterization of rare
FOXP2 variants in neurodevelopmental disorder. J. Neurodev.
Disord., 8, 354.
44. Jeon, B.-N., Choi, W.-I., Yu, M.-Y., Yoon, A.-R., Kim, M.-H.,
Yun, C.-O. and Hur, M.-W. (2009) ZBTB2, a novel master regu-
lator of the p53 pathway. J. Biol. Chem., 284, 17935–17946.
45. Ishida, H., Masuhiro, Y., Fukushima, A., Argueta, J.G.M.,
Yamaguchi, N., Shiota, S. and Hanazawa, S. (2005)
Identification and characterization of novel isoforms of
human DP-1: dP-1{alpha} regulates the transcriptional activ-
ity of E2F1 as well as cell cycle progression in a
dominant-negative manner. J. Biol. Chem., 280, 24642–24648.
46. Sun, S., Yang, X., Wang, Y. and Shen, X. (2016) In vivo analy-
sis of protein–protein interactions with bioluminescence
resonance energy transfer (BRET): progress and prospects.
Int. J. Mol. Sci., 17, 1704.
47. Hayes, S., Malacrida, B., Kiely, M. and Kiely, P.A. (2016)
Studying protein–protein interactions: progress, pitfalls and
solutions. Biochem. Soc. Trans., 44, 994–1004.
48. Budayeva, H.G. and Cristea, I.M. (2014) A mass spectrometry
view of stable and transient protein interactions. Adv. Exp.
Med. Biol., 806, 263–282.
49. Li, X., Wang, W., Wang, J., Malovannaya, A., Xi, Y., Li, W.,
Guerra, R., Hawke, D.H., Qin, J. and Chen, J. (2015) Proteomic
analyses reveal distinct chromatin-associated and soluble
transcription factor complexes.Mol. Sys. Biol., 11, 775–775.
50. Chan, C.M., Fulton, J., Montiel-Duarte, C., Collins, H.M.,
Bharti, N., Wadelin, F.R., Moran, P.M., Mongan, N.P. and
Heery, D.M. (2013) A signature motif mediating selective
interactions of BCL11A with the NR2E/F subfamily of orphan
nuclear receptors.Nucleic Acids Res., 41, 9663–9679.
51. Vernes, S.C., Nicod, J., Elahi, F.M., Coventry, J.A., Kenny, N.,
Coupe, A.-M., Bird, L.E., Davies, K.E. and Fisher, S.E. (2006)
Functional genetic analysis of mutations implicated in a
human speech and language disorder. Hum. Mol. Genet., 15,
3154–3167.
52. Lai, T., Jabaudon, D., Molyneaux, B.J., Azim, E., Arlotta, P.,
Menezes, J.R.L. and Macklis, J.D. (2008) SOX5 controls the
sequential generation of distinct corticofugal neuron sub-
types. Neuron, 57, 232–247.
53. Huang, Y., Zhang, L., Song, N.-N., Hu, Z.-L., Chen, J.-Y. and
Ding, Y.-Q. (2011) Distribution of Satb1 in the central nervous
system of adult mice.Neurosci. Res., 71, 12–21.
1225Human Molecular Genetics, 2018, Vol. 27, No. 7 |
Downloaded from https://academic.oup.com/hmg/article-abstract/27/7/1212/4819278
by Erasmus Universiteit Rotterdam user
on 16 April 2018
54. Kim, B.J., Takamoto, N., Yan, J., Tsai, S.Y. and Tsai, M.-J. (2009)
Chicken Ovalbumin Upstream Promoter-Transcription Factor
II (COUP-TFII) regulates growth and patterning of the postna-
talmouse cerebellum.Dev. Biol., 326, 378–391.
55. Tripodi, M., Filosa, A., Armentano, M. and Studer, M. (2004)
The COUP-TF nuclear receptors regulate cell migration in
the mammalian basal forebrain. Development, 131,
6119–6129.
56. Szemes, M., Gyorgy, A., Paweletz, C., Dobi, A. and Agoston,
D.V. (2006) Isolation and characterization of SATB2, a novel
AT-rich DNA binding protein expressed in development-
and cell-specific manner in the rat brain. Neurochem. Res., 31,
237–246.
57. Alvarez, J.D., Yasui, D.H., Niida, H., Joh, T., Loh, D.Y. and
Kohwi-Shigematsu, T. (2000) The MAR-binding protein
SATB1 orchestrates temporal and spatial expression of mul-
tiple genes during T-cell development. Genes Dev., 14,
521–535.
58. Denaxa, M., Kalaitzidou, M., Garefalaki, A., Achimastou, A.,
Lasrado, R., Maes, T. and Pachnis, V. (2012)
Maturation-promoting activity of SATB1 in MGE-derived
cortical interneurons. Cell Rep., 2, 1351–1362.
59. Balamotis, M.A., Tamberg, N., Woo, Y.J., Li, J., Davy, B.,
Kohwi-Shigematsu, T. and Kohwi, Y. (2012) Satb1 ablation
alters temporal expression of immediate early genes and
reduces dendritic spine density during postnatal brain
development.Mol. Cell. Biol., 32, 333–347.
60. Armentano, M., Filosa, A., Andolfi, G. and Studer, M. (2006)
COUP-TFI is required for the formation of commissural pro-
jections in the forebrain by regulating axonal growth.
Development, 133, 4151–4162.
61. Armentano, M., Chou, S.-J., Tomassy, G.S., Leinga¨rtner, A.,
O’Leary, D.D.M. and Studer, M. (2007) COUP-TFI regulates the
balance of cortical patterning between frontal/motor and
sensory areas.Nat. Neurosci., 10, 1277–1286.
62. Faedo, A., Tomassy, G.S., Ruan, Y., Teichmann, H., Krauss, S.,
Pleasure, S.J., Tsai, S.Y., Tsai, M.-J., Studer, M. and
Rubenstein, J.L.R. (2008) COUP-TFI coordinates cortical pat-
terning, neurogenesis, and laminar fate and modulates
MAPK/ERK, AKT, and beta-catenin signaling. Cereb. Cortex,
18, 2117–2131.
63. Tomassy, G.S., De Leonibus, E., Jabaudon, D., Lodato, S.,
Alfano, C., Mele, A., Macklis, J.D. and Studer, M. (2010)
Area-specific temporal control of corticospinal motor neu-
ron differentiation by COUP-TFI. Proc. Natl. Acad. Sci. U.S.A,
107, 3576–3581.
64. Usui, N., Co, M., Harper, M., Rieger, M.A., Dougherty, J.D. and
Konopka, G. (2016) Sumoylation of FOXP2 Regulates Motor
Function and Vocal Communication Through Purkinje Cell
Development. Biol. Psychiatry, 81, 220–230.
65. Groszer, M., Keays, D.A., Deacon, R.M.J., de Bono, J.P., Prasad-
Mulcare, S., Gaub, S., Baum, M.G., French, C.A., Nicod, J.,
Coventry, J.A. et al. (2008) Impaired synaptic plasticity and
motor learning in mice with a point mutation implicated in
human speech deficits. Curr. Biol., 18, 354–362.
66. Tam, W.Y., Leung, C.K.Y., Tong, K.K. and Kwan, K.M. (2011)
Foxp4 is essential in maintenance of Purkinje cell dendritic
arborization in the mouse cerebellum. Neuroscience, 172,
562–571.
67. Nesbitt, A., Bhoj, E.J., McDonald Gibson, K., Yu, Z.,
Denenberg, E., Sarmady, M., Tischler, T., Cao, K., Dubbs, H.,
Zackai, E.H. et al. (2015) Exome sequencing expands the
mechanism of SOX5-associated intellectual disability: a case
presentation with review of sox-related disorders. Am. J.
Med. Genet. A, 167, 2548–2554.
68. Lamb, A.N., Rosenfeld, J.A., Neill, N.J., Talkowski, M.E.,
Blumenthal, I., Girirajan, S., Keelean-Fuller, D., Fan, Z.,
Pouncey, J., Stevens, C. et al. (2012) Haploinsufficiency of
SOX5 at 12p12.1 is associated with developmental delays
with prominent language delay, behavior problems, and
mild dysmorphic features. Hum. Mutat., 33, 728–740.
69. Zarate, Y.A. and Fish, J.L. (2016) SATB2-associated syndrome:
mechanisms, phenotype, and practical recommendations.
Am. J. Med. Genet. A, 173, 327–337.
70. Bengani, H., Handley, M., Alvi, M., Ibitoye, R., Lees, M., Lynch,
S.A., Lam, W., Fannemel, M., Nordgren, A., Malmgren, H.
et al. (2017) Clinical and molecular consequences of
disease-associated de novo mutations in SATB2. Genet. Med.,
19, 900–908.
71. Zarate, Y.A., Kalsner, L., Basinger, A., Jones, J.R., Li, C.,
Szybowska, M., Xu, Z.L., Vergano, S., Caffrey, A.R., Gonzalez,
C.V. et al. (2017) Genotype and Phenotype in 12 additional
individuals with SATB2-Associated Syndrome. Clin. Genet.,
92, 423–429.
72. Bosch, D.G.M., Boonstra, F.N., Gonzaga-Jauregui, C., Xu, M.,
de Ligt, J., Jhangiani, S., Wiszniewski, W., Muzny, D.M.,
Yntema, H.G., Pfundt, R. et al. (2014) NR2F1 mutations cause
optic atrophy with intellectual disability. Am. J. Hum. Genet.,
94, 303–309.
73. Chen, C.-A., Bosch, D.G.M., Cho, M.T., Rosenfeld, J.A.,
Shinawi, M., Lewis, R.A., Mann, J., Jayakar, P., Payne, K.,
Walsh, L. et al. (2016) The expanding clinical phenotype of
Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new
cases and possible genotype-phenotype correlations. Genet.
Med., 18, 1143–1150.
74. Gabriele, M., Vulto-van Silfhout, A.T., Germain, P.-L.,
Vitriolo, A., Kumar, R., Douglas, E., Haan, E., Kosaki, K.,
Takenouchi, T., Rauch, A. et al. (2017) YY1 Haploinsufficiency
Causes an Intellectual Disability Syndrome Featuring
Transcriptional and Chromatin Dysfunction. Am. J. Hum.
Genet., 100, 907–925.
75. Vissers, L.E.L.M., de Ligt, J., Gilissen, C., Janssen, I.,
Steehouwer, M., de Vries, P., van Lier, B., Arts, P., Wieskamp,
N., del Rosario, M. et al. (2010) A de novo paradigm for mental
retardation. Nat. Genet., 42, 1109–1112.
76. Neale, B.M., Kou, Y., Liu, L., Ma’ayan, A., Samocha, K.E., Sabo,
A., Lin, C.-F., Stevens, C., Wang, L.-S., Makarov, V. et al. (2012)
Patterns and rates of exonic de novo mutations in autism
spectrum disorders.Nature, 485, 242–245.
77. Stevens, S.J.C., van Essen, A.J., van Ravenswaaij, C.M.A.,
Elias, A.F., Haven, J.A., Lelieveld, S.H., Pfundt, R., Nillesen,
W.M., Yntema, H.G., van Roozendaal, K. et al. (2016)
Truncating de novo mutations in the Kru¨ppel-type
zinc-finger gene ZNF148 in patients with corpus callosum
defects, developmental delay, short stature, and dysmor-
phisms. Genome Med., 8, 131.
78. Greig, L.C., Woodworth, M.B., Galazo, M.J., Padmanabhan, H.
and Macklis, J.D. (2013) Molecular logic of neocortical projec-
tion neuron specification, development and diversity. Nat.
Rev. Neurosci., 14, 755–769.
79. Shim, S., Kwan, K.Y., Li, M., Lefebvre, V. and Sestan, N. (2012)
Cis-regulatory control of corticospinal system development
and evolution. Nature, 486, 74–79.
80. Han, W., Kwan, K.Y., Shim, S., Lam, M.M.S., Shin, Y., Xu, X.,
Zhu, Y., Li, M. and Sestan, N. (2011) TBR1 directly represses
Fezf2 to control the laminar origin and development of the
corticospinal tract. Proc. Natl. Acad. Sci. U.S.A, 108, 3041–3046.
1226 | Human Molecular Genetics, 2018, Vol. 27, No. 7
Downloaded from https://academic.oup.com/hmg/article-abstract/27/7/1212/4819278
by Erasmus Universiteit Rotterdam user
on 16 April 2018
81. McKenna, W.L., Ortiz-Londono, C.F., Mathew, T.K., Hoang,
K., Katzman, S. and Chen, B. (2015) Mutual regulation
between Satb2 and Fezf2 promotes subcerebral projection
neuron identity in the developing cerebral cortex. Proc. Natl.
Acad. Sci. U.S.A, 112, 11702–11707.
82. Alcamo, E.A., Chirivella, L., Dautzenberg, M., Dobreva, G.,
Fari~nas, I., Grosschedl, R. and McConnell, S.K. (2008) Satb2
regulates callosal projection neuron identity in the develop-
ing cerebral cortex. Neuron, 57, 364–377.
83. Britanova, O., de Juan Romero, C., Cheung, A., Kwan, K.Y.,
Schwark, M., Gyorgy, A., Vogel, T., Akopov, S., Mitkovski, M.,
Agoston, D. et al. (2008) Satb2 is a postmitotic determinant
for upper-layer neuron specification in the neocortex.
Neuron, 57, 378–392.
84. Ca´novas, J., Berndt, F.A., Sepu´lveda, H., Aguilar, R., Veloso,
F.A., Montecino, M., Oliva, C., Maass, J.C., Sierralta, J. and
Kukuljan, M. (2015) The specification of cortical subcerebral
projection neurons depends on the direct repression of TBR1
by CTIP1/BCL11a. J. Neurosci., 35, 7552–7564.
85. Dias, C., Estruch, S.B., Graham, S.A., McRae, J., Sawiak, S.J.,
Hurst, J.A., Joss, S.K., Holder, S.E., Morton, J.E.V., Turner, C.
et al. (2016) BCL11A haploinsufficiency causes an intellectual
disability syndrome and dysregulates transcription. Am. J.
Hum. Genet., 99, 253–274.
86. Lumish, H.S., Wynn, J., Devinsky, O. and Chung, W.K. (2015)
Brief report: sETD2mutation in a child with autism, intellec-
tual disabilities and epilepsy. J. Autism. Dev. Disord., 45,
3764–3770.
87. Luscan, A., Laurendeau, I., Malan, V., Francannet, C.,
Odent, S., Giuliano, F., Lacombe, D., Touraine, R., Vidaud,
M., Pasmant, E. et al. (2014) Mutations in SETD2
cause a novel overgrowth condition. J. Med. Genet., 51,
512–517.
88. Wang, B., Weidenfeld, J., Lu, M.M., Maika, S., Kuziel, W.A.,
Morrisey, E.E. and Tucker, P.W. (2004) Foxp1 regulates car-
diac outflow tract, endocardial cushion morphogenesis and
myocyte proliferation and maturation. Development, 131,
4477–4487.
89. Li, S., Zhou, D., Lu, M.M. and Morrisey, E.E. (2004) Advanced
cardiac morphogenesis does not require heart tube fusion.
Science, 305, 1619–1622.
90. Al Turki, S., Manickaraj, A.K., Mercer, C.L., Gerety, S.S., Hitz,
M.-P., Lindsay, S., D’Alessandro, L.C.A., Swaminathan, G.J.,
Bentham, J. and Arndt, A.-K. (2014) Rare variants in NR2F2
cause congenital heart defects in humans. Am. J. Hum.
Genet., 94, 574–585.
91. Beketaev, I., Zhang, Y., Kim, E.Y., Yu, W., Qian, L. and Wang,
J. (2015) Critical role of YY1 in cardiac morphogenesis. Dev.
Dyn, 244, 669–680.
92. Kim, J., Cantor, A.B., Orkin, S.H. and Wang, J. (2009) Use of
in vivo biotinylation to study protein–protein and
protein-DNA interactions in mouse embryonic stem cells.
Nat. Protoc., 4, 506–517.
93. van den Berg, D.L.C., Snoek, T., Mullin, N.P., Yates, A.,
Bezstarosti, K., Demmers, J., Chambers, I. and Poot, R.A.
(2010) An Oct4-centered protein interaction network in
embryonic stem cells. Cell Stem Cell, 6, 369–381.
94. Engelen, E., Akinci, U., Bryne, J.C., Hou, J., Gontan, C., Moen,
M., Szumska, D., Kockx, C., van Ijcken, W., Dekkers, D.H.W.
et al. (2011) Sox2 cooperates with Chd7 to regulate genes that
are mutated in human syndromes.Nat. Genet., 43, 607–611.
95. Gagliardi, A., Mullin, N.P., Ying Tan, Z., Colby, D., Kousa, A.I.,
Halbritter, F., Weiss, J.T., Felker, A., Bezstarosti, K., Favaro, R.
et al. (2013) A direct physical interaction between Nanog and
Sox2 regulates embryonic stem cell self-renewal. EMBO J.,
32, 2231–2247.
96. Ninkovic, J., Steiner-Mezzadri, A., Jawerka, M., Akinci, U.,
Masserdotti, G., Petricca, S., Fischer, J., von Holst, A., Beckers, J.,
Lie, C.D. et al. (2013) The BAF complex interactswith Pax6 in adult
neural progenitors to establish a neurogenic cross-regulatory
transcriptional network.Cell StemCell, 13, 403–418.
97. Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.-P.,
St-Denis, N.A., Li, T., Miteva, Y.V., Hauri, S., Sardiu, M.E.,
Low, T.Y. et al. (2013) The CRAPome: a contaminant reposi-
tory for affinity purification-mass spectrometry data. Nat.
Methods, 10, 730–736.
1227Human Molecular Genetics, 2018, Vol. 27, No. 7 |
Downloaded from https://academic.oup.com/hmg/article-abstract/27/7/1212/4819278
by Erasmus Universiteit Rotterdam user
on 16 April 2018
